EVERETT, WASH. — Breakthrough, a joint venture of Tishman Speyer and Bellco Capital, has acquired a biomanufacturing facility in Everett, a suburb of Seattle, for $78 million. In tandem with the acquisition, Breakthrough secured a separate 21-year lease for the entire campus with a global biopharmarceutical company to create a U.S. manufacturing facility. The 270,000-square-foot facility can support a range of uses, including drug manufacturing, quality-control lab operations and, warehouse/distribution functions. The property also offers administrative office spaces and an onsite café. The site, located at 215 Shuksan Way, was originally leased to a biotechnology company that invested approximately $350 million to build out a biomanufacturing facility but never moved in after being acquired in 2023. The transaction marks Breakthrough’s first investment in the Puget Sound region. The name of the seller was not released.
